GlassScriptPhysician profile
Tonny M Lee
NPI 1639118748
$111,452.08
in general payments reported to CMS, 2019-2025
32 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,755 · 2021: $11K · 2022: $12K · 2023: $16K · 2024: $22K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $4,917 · Travel and Lodging: $169 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $51,500.00 |
| Food and Beverage | $4,917.36 |
| Travel and Lodging | $168.56 |
| Education | $102.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $68,636.21 | 2019-2025 | Vemlidy, Livdelzi |
| Abbvie INC. | $25,039.82 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $8,322.78 | 2019-2025 | Linzess |
| Allergan, INC. | $4,783.66 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,223.32 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $764.48 | 2019-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $428.19 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $393.37 | 2021-2024 | Zeposia |
| Pfizer INC. | $300.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.32 | 2019-2025 | Entyvio, Gattex |
| Merck Sharp & Dohme LLC | $147.98 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $128.85 | 2024-2025 | Vowst, Zenpep |
| Novo Nordisk INC | $124.99 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $121.20 | 2019-2025 | Ocaliva |
| Ardelyx, INC. | $82.23 | 2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $75.53 | 2020-2021 | |
| Alfasigma USA, INC. | $70.01 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $68.65 | 2022 | |
| Fresenius Kabi USA, LLC | $58.68 | 2023 | |
| Lilly USA, LLC | $55.56 | 2024-2025 | Omvoh |
| Genzyme Corporation | $55.12 | 2023-2025 | |
| Shionogi INC | $53.53 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $46.16 | 2024-2025 | Iqirvo |
| Braintree Laboratories, INC. | $41.52 | 2019-2024 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $31.45 | 2024 | Voquezna |
| Organon LLC | $30.88 | 2021-2023 | Renflexis |
| Amgen INC. | $26.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $22.32 | 2025 | Dupixent |
| Celltrion USA INC. | $21.78 | 2023 | Yuflyma |
| Intra-Sana Laboratories | $16.21 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $15.04 | 2024 | Cologuard Collection Kit |
| W. L. Gore & Associates, INC. | $12.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonny Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.